Click here to claim CME/NCPD credit for this activity: https://i3health.com/oda-gvhd

This audio includes both the additional updates interview and complete podcast from i3 Health’s CME/NCPD activity New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease.

First, listen along as Dr. Shernan Holtan shares the latest data from the BTM CTN 1703 trial of posttransplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as GVHD prophylaxis after allogeneic hematopoietic cell transplantation, then stay tuned after the interview to listen along to the full activity.